Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EC to amend requirements for HbsAg (hepatitis B antigen) reagents:

This article was originally published in Clinica

Executive Summary

The European Commission will need to amend in the near future the EU's Common Technical Specification (CTS) on hepatitis B antigen reagents (HbsAg) in the light of international developments. CTSs are technical requirements for IVDs that are more detailed than standards and considered by regulators as quasi mandatory. The reason for the change is that the World Health Organisation (WHO) is developing the first international standard on these products, which will become the reference standard for the European CTSs. At present the EU HbsAg CTS makes reference to the French and UK standards because of the absence to date of international work in this area. Representatives of the WHO and of the European Commission's medical devices unit are due to meet during the third week of October to discuss progress. The Commission is following the work carefully and has commented that the WHO is being "open and co-operative".

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT063684

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel